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Orthopedic oncology or the art and science
of management of musculoskeletal tumors
is one of the relatively newer sub specialties
in orthopedics.
The last few decades have seen rapid
strides in the field of musculoskele-
tal oncology with amputation no longer
remaining the only option to achieve local
control in malignant bone tumors. Func-
tion preserving alternatives in these lesions
have now become the norm without com-
promising on overall disease survival and
have resulted in a documented improve-
ment in overall quality of life of patients
(1). As surgeons, our goal posts have now
changed and the challenge has shifted. It
is no longer limited to just resection of
disease and restoration of function but
includes being able to go about this in the
most affordable manner. There is increas-
ing pressure for medical technology assess-
ment to include cost-effectiveness analy-
ses to help determine difficult resource
allocation decisions (2).
Additionally, there is also a pressing
need to create awareness about these
uncommon lesions, rapidly disseminate
and propagate current information and
techniques, train care givers from diverse
geographical backgrounds, set up collab-
orative networks to gain further insight
into these rare lesions and help develop
evidence based protocols.
More than 80% of the population of the
world is located in developing countries
where there exists considerable diversity
in terms of resource and expertise avail-
ability when it comes to managing mus-
culoskeletal lesions (3). The gamut ranges
from centers that offer the latest tech-
nological advances to surgeons forced to
resort to amputations due to infrastruc-
tural hurdles (4). Modern orthopedics is
expensive, and even personnel trained to
the highest theoretical and practical level
will have to continuously innovate and
improvise when confronted with economic
constraints (3). The absence of structured
training programs and opportunities in
developing countries results in a paucity
of trained musculoskeletal oncologists (5).
It is little wonder that a large number
of patients in some of these areas are
treated by inexperienced surgeons without
observing oncologic principles (6).
Various exchange initiatives where expe-
rienced surgeons travel to resource chal-
lenged areas to share their knowledge and
expertise serves as an excellent example of
a symbiotic relationship (7). The “expert”
helps the onsite medical team update their
knowledge and skills while stepping out-
side his “comfort zone” and being forced to
work with locally available resources (8).
This experience often results in develop-
ment of innovations, which with further
refinements provide cost-effective accept-
able alternative solutions globally. The var-
ious “musculoskeletal” and “bone tumor”
societies and associations need to strive
to promote such interactions by serving
as a bridge between the “trainer” and the
“trainees” (9).
Early diagnosis helps in achieving
improved outcomes for patients with can-
cer (10). Delays in diagnosing bone and soft
tissue sarcomas are frequent both because
of their rarity and because the clinical fea-
tures may be confused with other condi-
tions. There is a need to educate and cre-
ate awareness about these lesions. Unfor-
tunately, even among countries with well
developed health care networks there is
dichotomy in data from various centers
regarding the impact that awareness cam-
paigns and education have had on early
presentation and referral of bone and soft
tissue sarcomas. While Denmark demon-
strated that cancer patient pathways have
accelerated the diagnostic process for sar-
comas with a reduction in tumor size, the
UK showed almost no difference in size
at presentation over time (11, 12). There
is considerable room for improvements in
this sphere with an urgent need for new
strategies.
Alvin Toffler hits the nail on the head
when he says “The illiterate of the 21st cen-
tury will not be those who cannot read and
write, but those who cannot learn, unlearn,
and relearn.” Over the years, many beliefs
and practices become entrenched as tried
and tested, and we believe they are based
on scientific evidence (13). While today’s
“new age medicine” expounds the necessity
of tangible evidence for every clinical deci-
sion, the truth remains that observational
studies dominate orthopedic surgery litera-
ture (and most medical literature) forming
the basis for most therapeutic decisions
including those for bone tumors (14).
While the importance of clinical exper-
tise and experience is unquestionable, we
do need to combine this with the judicious
integration of best available scientific evi-
dence to facilitate rational “informed” clin-
ical decision making. The issue of antibi-
otic prophylaxis and post treatment sur-
veillance in bone tumors highlight just two
examples in orthopedic oncology where
guidelines based on evidence are lacking.
In a systematic review to determine
infection rates following endoprosthetic
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reconstruction in long bone tumors
the duration of antibiotic prophylaxis
ranged from “intraoperative dosing only”
to “>72 h.” Current clinical practice is
highly varied with respect to antibiotic
duration and there is a need to have evi-
dence based guidelines, not only to stream
line escalating healthcare costs but also
prevent antibiotic misuse and overuse,
which lead to antibiotic resistance, an issue
of increasing clinical importance. The
multicentre randomized control trial coor-
dinated by the Center for Evidence Based
Orthopaedics at McMaster University to
determine the optimal dosing regimen
among patients undergoing surgical exci-
sion and endoprosthetic reconstruction of
bone tumors is a commendable step to try
and fill this lacuna (15).
Modern multimodality therapy has
improved patient survival; hence, follow-
up surveillance strategies are becoming
increasingly important with significant
clinical and fiscal implications. Whether
an increased frequency of follow-up visits
and the use of various expensive imag-
ing modalities for screening and early
detection of recurrence actually results in
improving overall survival of patients with
sarcomas is a question that remains as yet
unanswered. The financial costs incurred
by surveillance are considerable and this
includes both the cost to the health ser-
vice and to the patient in terms of hos-
pital visits and lost working days. Ide-
ally, any follow-up program should be
able to prove that its benefits and sav-
ings exceed its risks and costs. Although
guidelines have been suggested for follow-
up of patients with sarcomas, there is a
paucity of data in medical literature on
the effectiveness of these recommenda-
tions. There is reasonable evidence in lit-
erature from other solid tumor types, i.e.,
breast cancer, colorectal cancer, endome-
trial cancer, and melanoma that chal-
lenges the usefulness of multiple follow-
up imaging tests in terms of efficacy,
cost-effectiveness, and survival benefit and
recent publications seem to support the
same surmise for bone and soft tissue
sarcomas (16, 17).
In an increasingly “cost conscious”
health care scenario, allocation of limited
health funding is best guided by these
newer evidence based recommendations
rather than empirical beliefs. We need to
rapidly develop the ability to “unlearn and
relearn” or else risk being condemned as
“illiterate.”
It is this ability to question, reason,
continually innovate, and find sustainable
solutions that distinguishes us from our
primate ancestors. These are qualities that
we must encourage and inculcate in our
colleagues and trainees. We need to stim-
ulate them to break free from the con-
straints of hierarchical acceptance of prac-
tices steeped in convention without solid
scientific merit. That would be one of the
best legacies that we could bestow on future
generations.
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